Everest Medicines and Dimerix have entered into an exclusive commercialization license agreement for DMX-200, filling a gap in FSGS treatment in China and deepening their commercialization footprint in the Asia-Pacific region.

Everest Medicines and Dimerix have entered into an exclusive commercialization license agreement for DMX-200, filling the treatment gap for FSGS in China and deepening the commercialization layout in the Asia-Pacific region.

Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive commercialization license agreement with Dimerix Limited (hereinafter referred to as "Dimerix"), obtaining the clinical development and commercialization rights for DMX-200 in Greater China (including Mainland China, Hong Kong, Macau, and Taiwan), South Korea, and several Southeast Asian countries (including Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines). This collaboration will further optimize Everest Medicines' nephrology product portfolio, enhance pipeline synergy efficiency, and strengthen the company's strategic position in the field of kidney and autoimmune diseases.

According to the agreement, Everest Medicines will pay Dimerix an upfront payment of $10 million, as well as development and registration milestone payments of up to $30 million and commercialization milestone payments of up to $300 million. In addition, Dimerix will receive tiered royalties ranging from 10% to 15% based on DMX-200's future annual net sales in the licensed territories.

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) and is currently undergoing the global pivotal phase III clinical study ACTION3 for the treatment of focal segmental glomerulosclerosis (FSGS). According to public information, DMX-200 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Mr. Wu Yifang, Chairman of the Board of Everest Medicines, stated: "This collaboration with Dimerix is an important step for the company to continuously expand its product portfolio in the nephrology field. For a long time, Chinese FSGS patients have lacked targeted treatments, resulting in significant unmet clinical needs. The positive interim analysis results from the global pivotal phase III clinical study of DMX-200 indicate its broad development prospects, offering the potential to provide new treatment options for patients and fill the treatment gap for FSGS in China. Leveraging the company's mature capabilities in clinical development, registration, and commercialization, we will accelerate the development and market launch process of DMX-200 in China and the Asia-Pacific market, and explore its application potential in other glomerular diseases. We look forward to working closely with Dimerix to bring this innovative therapy to more patients."

Dr. Nina Webster, Chief Executive Officer and Managing Director of Dimerix, said: "We are very pleased to collaborate with Everest Medicines. Everest Medicines has deep expertise in rare kidney diseases and possesses mature commercialization capabilities covering Greater China, South Korea, and Southeast Asian markets. This collaboration will significantly improve the accessibility of DMX-200 to patient populations in urgent need of treatment. With its extensive experience and resources in the licensed territories, Everest Medicines has the potential to fully unlock the clinical and commercial value of DMX-200. At the same time, Dimerix will continue to advance the global registrational clinical program, committed to creating long-term value for shareholders and bringing tangible and accessible treatment hope to FSGS patients worldwide."

The global pivotal phase III clinical study ACTION3 (Angiotensin II Type 1 Receptor & Chemokine Receptor 2 Targets for Inflammatory Nephrosis) is a multicenter, randomized, double-blind, placebo-controlled clinical study designed to evaluate the efficacy and safety of DMX-200 in combination with a stable dose of an angiotensin II receptor blocker (ARB) in patients with focal segmental glomerulosclerosis (FSGS). On the basis of receiving stable-dose ARB therapy, subjects are randomized to receive DMX-200 (120 mg, twice daily) or placebo. The ACTION3 study design includes two pre-specified interim analyses to evaluate key indicators such as proteinuria and renal function (estimated glomerular filtration rate slope).

To date, the study has completed enrollment of 333 patients globally. Positive interim analysis results announced in early 2024 showed that DMX-200 was significantly superior to placebo in reducing proteinuria. As of now, the Independent Data Monitoring Committee has completed 8 reviews, the most recent of which was conducted in June 2026, with no safety issues identified; furthermore, an external statistical blinded assessment indicates the study still has sufficient power (>90%) to verify the significant improvement in proteinuria by DMX-200 at the end of the study.

FSGS is a rare and severe kidney disease. Its main pathological feature is progressive sclerosis (scarring) in parts of the glomeruli, leading to proteinuria and gradual decline in renal function, which may eventually progress to end-stage renal disease. Current clinical treatment mainly relies on non-specific immunosuppressive and supportive therapies. According to estimates based on chronic kidney disease epidemiological models, the theoretical patient population size for focal segmental glomerulosclerosis in China may reach approximately 500,000 to 1 million people 1,2.

Compared to a single product license, this collaboration is viewed by the industry as an important step for Everest Medicines to continuously deepen its layout in the nephrology field. In recent years, the company has been building a nephrology product matrix around IgA nephropathy, chronic kidney disease, and other areas, including

Nefecon (R), EVER001 (Xibutinib), MT1013, and Beijiexin (R) (MIL62). The introduction of DMX-200 not only has the potential to fill the gap in innovative FSGS treatment in China but will also further enrich Everest Medicines' nephrology pipeline, creating synergies with existing products and R&D projects, and extending its nephrology strategy into broader chronic kidney disease areas.

At the same time, this collaboration covers multiple core markets in Greater China, South Korea, and Southeast Asia, further reflecting Everest Medicines' strategic direction to continuously improve its commercialization network in the Asia-Pacific region. The relevant regions have a large population base, with the burden of chronic diseases such as chronic kidney disease continuously rising, and significant unmet medical needs among patients. Everest Medicines is gradually expanding its accumulated commercialization experience to the broader Asia-Pacific market. With the continuous advancement of the "BD collaboration + in-house R&D" dual-drive model, Everest Medicines has the potential to further unlock the value of its innovative assets, opening up new possibilities for its long-term growth.